[{"id":"fd69b3ec-1305-4dd1-87d3-4b0c8f4a1b9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661384","created_at":"2025-06-07T14:44:26.057Z","updated_at":"2025-06-07T14:44:26.057Z","phase":"Phase 1","brief_title":"Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma","source_id_and_acronym":"NCT04661384","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD123","pipe":"","alterations":" ","tags":["CD123"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 11/17/2025","primary_completion_date":" 11/17/2025","study_txt":" Completion: 11/17/2025","study_completion_date":" 11/17/2025","last_update_posted":"2025-06-03"},{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"},{"id":"93a602fc-fef4-4ca8-ada5-f9aa24df7e29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720988","created_at":"2023-08-14T10:11:11.619Z","updated_at":"2025-02-25T15:45:00.769Z","phase":"Phase 1","brief_title":"Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05720988","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/03/2024","start_date":" 08/03/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2026","study_completion_date":" 08/03/2026","last_update_posted":"2024-03-08"},{"id":"9f422a88-402d-4776-a63e-899f8ce422df","acronym":"NCI-2014-01147","url":"https://clinicaltrials.gov/study/NCT02159495","created_at":"2021-01-18T10:03:02.202Z","updated_at":"2024-07-02T16:35:21.732Z","phase":"Phase 1","brief_title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT02159495 - NCI-2014-01147","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["FLT3 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-01-30"},{"id":"50591c7e-2bb2-4a10-8880-29d3224dc148","acronym":"PEPN1812","url":"https://clinicaltrials.gov/study/NCT04158739","created_at":"2023-12-11T17:16:23.292Z","updated_at":"2024-07-02T16:35:26.619Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04158739 - PEPN1812","lead_sponsor":"Children's Oncology Group","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-12-11"},{"id":"f871fea9-e2b8-4a4c-97ed-93bea378ea0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04510051","created_at":"2021-01-18T21:37:11.984Z","updated_at":"2024-07-02T16:35:34.277Z","phase":"Phase 1","brief_title":"CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children","source_id_and_acronym":"NCT04510051","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD123","pipe":" | ","alterations":" CD123 expression","tags":["CD123"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 08/24/2024","primary_completion_date":" 08/24/2024","study_txt":" Completion: 08/24/2024","study_completion_date":" 08/24/2024","last_update_posted":"2023-10-09"},{"id":"8d195ac4-ff45-457f-b006-0abe5f018000","acronym":"","url":"https://clinicaltrials.gov/study/NCT06006403","created_at":"2023-08-23T15:10:48.638Z","updated_at":"2024-07-02T16:35:38.691Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT06006403","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA positive","tags":["IL6 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD123 targeted CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-30"},{"id":"35ca491d-0cc1-434a-914b-6dc84cb52011","acronym":"","url":"https://clinicaltrials.gov/study/NCT05574608","created_at":"2022-10-10T14:05:46.075Z","updated_at":"2024-07-02T16:35:49.544Z","phase":"Phase 1","brief_title":"Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia","source_id_and_acronym":"NCT05574608","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JD023"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2023-04-26"},{"id":"23fe5699-b91c-473a-b6f8-99a276ffb074","acronym":"","url":"https://clinicaltrials.gov/study/NCT04272125","created_at":"2021-01-18T20:45:10.451Z","updated_at":"2024-07-02T16:35:50.369Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04272125","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"2f6c09fe-648a-43a4-b8de-c7035dd17c75","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265963","created_at":"2021-01-18T20:43:42.945Z","updated_at":"2024-07-02T16:35:50.304Z","phase":"Phase 1/2","brief_title":"CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04265963","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"ef9f33ba-d081-412c-af8d-bf768df5b986","acronym":"","url":"https://clinicaltrials.gov/study/NCT02715011","created_at":"2021-01-18T13:16:28.170Z","updated_at":"2024-07-02T16:36:25.083Z","phase":"Phase 1","brief_title":"Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT02715011","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-63709178"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 03/26/2021","primary_completion_date":" 03/26/2021","study_txt":" Completion: 03/26/2021","study_completion_date":" 03/26/2021","last_update_posted":"2021-08-31"},{"id":"0f73e762-cc4d-4587-b6bb-5b28a5196876","acronym":"","url":"https://clinicaltrials.gov/study/NCT04430530","created_at":"2021-01-18T21:20:13.869Z","updated_at":"2024-07-02T16:36:44.211Z","phase":"Phase 1/2","brief_title":"4SCAR-T Therapy Post CD19-targeted Immunotherapy","source_id_and_acronym":"NCT04430530","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD38 • CD123 • CD22 • MME • IL3RA","pipe":"","alterations":" ","tags":["CD20 • CD38 • CD123 • CD22 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"},{"id":"302a874f-6617-4986-8f96-30d12232b833","acronym":"","url":"https://clinicaltrials.gov/study/NCT03125577","created_at":"2021-01-18T15:23:58.289Z","updated_at":"2024-07-02T16:36:55.542Z","phase":"Phase 1/2","brief_title":"Combination CAR-T Cell Therapy Targeting Hematological Malignancies","source_id_and_acronym":"NCT03125577","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD19 • TNFRSF8 • CD38 • CD123 • CD22 • CD70 • IL3RA","pipe":" | ","alterations":" TNFRSF8 expression • CD20 expression • CD19 expression","tags":["CD20 • CD19 • TNFRSF8 • CD38 • CD123 • CD22 • CD70 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • CD20 expression • CD19 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 07/31/2019","primary_completion_date":" 07/31/2019","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2019-09-19"},{"id":"78e1680d-703f-4e5f-957a-df94de13cc39","acronym":"","url":"https://clinicaltrials.gov/study/NCT04014881","created_at":"2021-01-18T19:43:13.211Z","updated_at":"2024-07-02T16:36:57.207Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.","source_id_and_acronym":"NCT04014881","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD123 CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 07/06/2019","start_date":" 07/06/2019","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2019-08-07"},{"id":"fb7d666c-54c6-4059-a090-52088390aea8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02937103","created_at":"2021-01-18T14:25:20.027Z","updated_at":"2024-07-02T16:36:58.622Z","phase":"Phase 1/2","brief_title":"A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies","source_id_and_acronym":"NCT02937103","lead_sponsor":"Southwest Hospital, China","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"],"overall_status":"Unknown status","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2019-06-25"},{"id":"d7c95ee1-956c-45c4-a831-43623a7594bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556982","created_at":"2021-01-18T17:30:30.309Z","updated_at":"2024-07-02T16:37:10.067Z","phase":"Phase 1/2","brief_title":"CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）","source_id_and_acronym":"NCT03556982","lead_sponsor":"The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTL123"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2018-06-14"},{"id":"87960e4c-f8f4-42fa-8dc0-d2e367b6ad0c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03249636","created_at":"2021-01-18T16:03:17.915Z","updated_at":"2024-07-02T16:37:18.394Z","phase":"","brief_title":"New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03249636","lead_sponsor":"Assiut University","biomarkers":" CD123 • CEACAM6","pipe":" | ","alterations":" CD123 expression","tags":["CD123 • CEACAM6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2017-08-29"},{"id":"24dd0f83-5501-426c-b044-d1a1395f1d4b","acronym":"IMAGE","url":"https://clinicaltrials.gov/study/NCT02176447","created_at":"2021-01-18T10:08:36.865Z","updated_at":"2024-07-02T16:37:28.245Z","phase":"","brief_title":"Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer","source_id_and_acronym":"NCT02176447 - IMAGE","lead_sponsor":"Universitaire Ziekenhuizen Leuven","biomarkers":" HER-2 • ER • CD20 • CDKN2A • CD123 • NCAM1 • CD14 • ITGAM • IL3RA • ITGAX","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • CD20 • CDKN2A • CD123 • NCAM1 • CD14 • ITGAM • IL3RA • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2016-10-25"}]